Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates | JCO Clinical Cancer Informatics
Durable Response Rate
Efficacy I PLUVICTO
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM
Overall response rate | Download Table
Zacks Small Cap Research - ONCS: New Data Provide Evidence that ImmunoPulse IL-12 Can Prime the Immune System
Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine
Efficacy - Overall Response Rate | Aliqopa US HCP
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
Cell therapy doubles survival, response rates in advanced melanoma
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial | Nature Medicine
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Objective Response Rate
ODOMZO® (sonidegib) | Efficacy Data
ORR (Objective Response Rate) and related statistics – Part 1
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris | BioSpace
Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
RESONATE-2 - Overall Response Rate | IMBRUVICA® (ibrutinib) HCP
Efficacy endpoints in Oncology
Best Overall Response Rate (full analysis population) | Download Table
